JANX logo

Janux Therapeutics, Inc. (JANX) EBITDA

Annual EBITDA:

-$96.79M-$25.76M(-36.27%)
December 31, 2024

Summary

  • As of today, JANX annual EBITDA is -$96.79 million, with the most recent change of -$25.76 million (-36.27%) on December 31, 2024.
  • During the last 3 years, JANX annual EBITDA has fallen by -$63.97 million (-194.94%).
  • JANX annual EBITDA is now -2470.70% below its all-time high of -$3.77 million, reached on December 31, 2019.

Performance

JANX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherJANXincome statement metrics

Quarterly EBITDA:

-$34.75M+$9.83M(+22.05%)
September 30, 2025

Summary

  • As of today, JANX quarterly EBITDA is -$34.75 million, with the most recent change of +$9.83 million (+22.05%) on September 30, 2025.
  • Over the past year, JANX quarterly EBITDA has increased by +$582.00 thousand (+1.65%).
  • JANX quarterly EBITDA is now -4117.23% below its all-time high of -$824.00 thousand, reached on March 31, 2020.

Performance

JANX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherJANXincome statement metrics

TTM EBITDA:

-$142.22M+$582.00K(+0.41%)
September 30, 2025

Summary

  • As of today, JANX TTM EBITDA is -$142.22 million, with the most recent change of +$582.00 thousand (+0.41%) on September 30, 2025.
  • Over the past year, JANX TTM EBITDA has dropped by -$58.33 million (-69.54%).
  • JANX TTM EBITDA is now -17159.10% below its all-time high of -$824.00 thousand, reached on March 31, 2020.

Performance

JANX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherJANXincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

JANX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-36.3%+1.6%-69.5%
3Y3 Years-194.9%-95.5%-130.1%
5Y5 Years-2470.7%-2668.9%-4366.6%

JANX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-194.9%at low-161.0%+22.1%-130.1%+0.4%
5Y5-Year-2470.7%at low-2668.9%+22.1%-4366.6%+0.4%
All-TimeAll-Time-2470.7%at low-4117.2%+22.1%>-9999.0%+0.4%

JANX EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$34.75M(+22.0%)
-$142.22M(+0.4%)
Jun 2025
-
-$44.58M(-29.7%)
-$142.80M(-28.0%)
Mar 2025
-
-$34.38M(-20.6%)
-$111.54M(-15.2%)
Dec 2024
-$96.79M(-36.3%)
-$28.51M(+19.3%)
-$96.79M(-15.4%)
Sep 2024
-
-$35.33M(-165.3%)
-$83.88M(-31.3%)
Jun 2024
-
-$13.32M(+32.2%)
-$63.86M(+9.8%)
Mar 2024
-
-$19.63M(-25.8%)
-$70.83M(+0.3%)
Dec 2023
-$71.02M(-7.2%)
-$15.61M(-1.9%)
-$71.02M(+3.1%)
Sep 2023
-
-$15.31M(+24.5%)
-$73.28M(+3.2%)
Jun 2023
-
-$20.28M(-2.3%)
-$75.74M(-4.3%)
Mar 2023
-
-$19.83M(-11.0%)
-$72.62M(-9.6%)
Dec 2022
-$66.25M
-$17.86M(-0.5%)
-$66.25M(-7.2%)
DateAnnualQuarterlyTTM
Sep 2022
-
-$17.77M(-3.6%)
-$61.81M(-12.6%)
Jun 2022
-
-$17.15M(-27.4%)
-$54.92M(-24.8%)
Mar 2022
-
-$13.46M(-0.3%)
-$44.00M(-34.1%)
Dec 2021
-$32.82M(-399.9%)
-$13.43M(-23.4%)
-$32.82M(-69.2%)
Sep 2021
-
-$10.88M(-74.3%)
-$19.39M(-98.5%)
Jun 2021
-
-$6.24M(-174.2%)
-$9.77M(-110.8%)
Mar 2021
-
-$2.27M(-81.3%)
-$4.63M(-45.6%)
Dec 2020
-$6.57M(-74.4%)
-
-
Sep 2020
-
-$1.25M(-13.6%)
-$3.18M(-65.1%)
Jun 2020
-
-$1.10M(-34.1%)
-$1.93M(-134.1%)
Mar 2020
-
-$824.00K
-$824.00K
Dec 2019
-$3.77M
-
-

FAQ

  • What is Janux Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Janux Therapeutics, Inc.?
  • What is Janux Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Janux Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Janux Therapeutics, Inc.?
  • What is Janux Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Janux Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Janux Therapeutics, Inc.?
  • What is Janux Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Janux Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of JANX is -$96.79M

What is the all-time high annual EBITDA for Janux Therapeutics, Inc.?

Janux Therapeutics, Inc. all-time high annual EBITDA is -$3.77M

What is Janux Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, JANX annual EBITDA has changed by -$25.76M (-36.27%)

What is Janux Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of JANX is -$34.75M

What is the all-time high quarterly EBITDA for Janux Therapeutics, Inc.?

Janux Therapeutics, Inc. all-time high quarterly EBITDA is -$824.00K

What is Janux Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, JANX quarterly EBITDA has changed by +$582.00K (+1.65%)

What is Janux Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of JANX is -$142.22M

What is the all-time high TTM EBITDA for Janux Therapeutics, Inc.?

Janux Therapeutics, Inc. all-time high TTM EBITDA is -$824.00K

What is Janux Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, JANX TTM EBITDA has changed by -$58.33M (-69.54%)
On this page